A multi-center, randomized, double-blind, parallel group study to evaluate the efficacy, tolerability and safety of 40 mg of Copaxone [glatiramer acetate] in the treatment of relapsing-remitting multiple sclerosis patients.

Trial Profile

A multi-center, randomized, double-blind, parallel group study to evaluate the efficacy, tolerability and safety of 40 mg of Copaxone [glatiramer acetate] in the treatment of relapsing-remitting multiple sclerosis patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Teva Neuroscience; Teva Pharmaceutical Industries
  • Most Recent Events

    • 17 Dec 2009 Actual patient number (90) added as reported by ClinicalTrials.gov.
    • 03 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top